Selected Articles On Prostate Cancer Published by Murphy Foundation Scientists in Peer-Reviewed Scientific Journals

spongereasonInternet and Web Development

Nov 12, 2013 (4 years ago)

440 views

Selected Articles On Prostate Cancer Published by Murphy
Foundation Scientists in Peer
-
Reviewed Scientific Journals



Prostate Cancer

Animal and Cellular Models



Schoonees R, Reynoso G,
Murphy GP
. The effect of androgen on canine prostatic
secretion.
J

Surg Oncol

1972; 4(3):169
-
179.


Varkarakis MJ, Kirdani RY, Abramczyk J,
Murphy GP
, Sandberg AA. Effects of
castration, androgens, and estrogens on steroid levels in the dog prostate.
Invest Urol

1973; 11(2):106
-
113.


Muntzing J,
Murphy GP
. Study on the

growth limiting mechanisms in the rat ventral
prostate.
Proc Soc Exp Biol Med

1977; 154(3):331
-
336.


Muntzing J, Kirdani RY,
Murphy GP
, Sandberg AA. A rat prostatic adenocarcinoma as
a model for the human disease.
Invest Urol

1979; 17(1):37
-
41.


Horosz
ewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA,
Murphy GP
. LNCaP model of human prostatic carcinoma.
Cancer Res

1983;
43(4):1809
-
1818.



Kadohama N, Wakisaka M, Karr JP,
Murphy GP
, Sandberg A. Retardation of
prostatic tumor prog
ression in the Noble rat by 4
-
methyl
-
4aza
-
steroidal inhibitors of 5α
-
reductase.
J Natl Cancer Inst

1985; 74(2):475
-
486.


Waters DJ
, Janovitz EB, Chan TCK. Spontaneous metastasis of PC
-
3 cells in athymic
mice after implantation in orthotopic or ectopic mi
croenvironments.
Prostate

1995;
26:227
-
234.


Waters DJ
, Bostwick DG. The canine prostate is a spontaneous model of intraepithelial
neoplasia and prostate cancer progression.
Anticancer Res

1997; 17:1467
-
1470.


Waters DJ
, Hayden DW, Bell FW, Klausner JS,

Qian J, Bostwick DG. Prostatic
intraepithelial neoplasia in dogs with spontaneous prostate cancer.
Prostate

1997; 30:2
-
97.


Waters DJ
and Bostwick DG. Prostatic intraepithelial neoplasia occurs spontaneously in
the canine prostate.
J Urol
1997; 157:71
3
-
716.


Waters DJ
, Sakr WA, Hayden DW, Lang CM, McKinney L,
Murphy GP
, Radinsky R,
Ramoner R, Richardson RC, Tindall DJ. Workgroup 4: Spontaneous prostate carcinoma
in dogs and nonhuman primates.
Prostate

1998; 36:64
-
67.



Waters DJ
, Bostwick DG,
Murphy

GP
. Conference summary: First International
Workshop on Animal Models of Prostate Cancer.
Prostate

1998; 36(1):47
-
48.


Aquilina JW, McKinney L, Pacelli A, Richman LK,
Waters DJ
, Thompson I, Burghardt
Jr. WF, Bostwick DG. High
-
grade prostatic intraepith
elial neoplasia in military working
dogs with and without prostate cancer.
Prostate

1998; 36:189
-
193.


Waters DJ
. High grade prostatic intraepithelial neoplasia in dogs.
Eur Urol

1999;
35:456
-
458.


Hayden DW, Klausner JS,
Waters DJ
. Prostatic leiomyosarc
oma in a dog:
clinicopathologic and immunohistochemical findings.
J Vet Diag Invest

1999; 11:283
-
286.



Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU,
Render JA, Stoica G, Sweet D,
Waters DJ
. Clinical and pathologic aspects
of
spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases.
Prostate

2000; 45:173
-
183.



Prostate Cancer
--
Biology


Murphy GP
, Bradley J. Primary sarcoma of the prostate.
J Urol

1961; 85(6):973
-
976.


Varkarakis MJ, Winterberger AR, Ga
eta J, Moore RH,
Murphy GP
. Lung metastases in
prostatic carcinoma: clinical significance.
Urology

1974; 3(4):447
-
452.


Gaeta JF, Asirwatham JE, Miller G,
Murphy GP
. Histologic grading of primary
prostatic cancer: a new approach to an old problem.
J Ur
ol

1979; 123(5):689
-
693.


Madajewicz S, Wajsman Z, Slack N, Mittelman A,
Murphy GP
. Insulin
-
induced growth
hormone responses in patients with prostatic carcinoma.
Urology

1979; 13(5)490
-
493.


Huben R, Matarajan N, Pontes E, Mettlin C, Smart CR,
Murphy GP
. Carcinoma of the
prostate in men less than 50 years old: data from American College of Surgeons’
National Survey.
Urology

1982; 20(6):585
-
588.


Mettlin C,
Murphy GP
, Menck H. Trends in treatment of localized prostate cancer by
radical prostatectomy: o
bservations from the Commission on Cancer National Cancer
Data Base, 1985
-
1990.
Urology

1993; 43(4):488
-
492.


Horoszewicz JS,
Murphy GP
. Prospective new developments in laboratory research and
clinical trials in prostate cancer.
Cancer

1990; 66(5):1083
-
1085.


Bostwick DG, Graham SD, Napalkov P, Abrahamsson PA, Di Sant’Agnese PA, Algaba
F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK, Denis L, Schroeder F,
Murphy GP
.
Staging of early prostate cancer: a proposed tumor volume
-
based prognostic index.
Urology

1993; 41(5):403
-
411.


Montironi R, Bostwick DG, Bonkhoff H, Cockett A, Helpap B, Troncoso P,
Waters DJ
.
Origins of prostate cancer.
Cancer

1996; 78:362
-
365.


Murphy GP
, von Eschenbach A, Bostwick DG. International consultation on prostatic
intraepithel
ial neoplasia and pathologic staging of prostatic carcinoma.
Cancer

1996;
78(2):324
-
325.


Helpap B, Bonkhoff H, Cockett A, Montironi R, Troncoso P,
Waters DJ,

Bostwick DG.
Relationship between atypical adenomatous hyperplasia (AAH), prostatic intraepithe
lial
neoplasia (PIN) and prostatic adenocarcinoma.
Pathologica

1997; 89:288
-
300.


Mettlin CJ,
Murphy GP
, Cunningham MP, Menck HR. The National Cancer Data Base
report on race, age, and region variations in prostate cancer treatment.
Cancer

1997;
80(7):1
261
-
1266.


Walker
-
Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ,
Waters DJ
, Kinch MS. Overexpression of the EphA2 tyrosine kinase in prostate cancer.
Prostate

1999; 41:275
-
280.


Drachenberg DE, Elgamal A
-
A A, Rowbotham R, Peterso
n M,
Murphy GP
. Circulating
levels of interleukin
-
6 in patients with hormone refractory prostate cancer.
Prostate

1999; 41:127
-
133.



Prostate Cancer
--
Chemotherapy


Scott WW, Johnson DE, Schmidt JE, Gibbons RP, Joiner JR, Saroff J,
Murphy GP
.
Chemothera
py of advanced prostatic carcinoma with cyclophosphamide or 5
-
fluorouracil: results of first national randomized study.
J Urol

1975; 114(6):909
-
911.


Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J,
Murphy GP
.
The continued evaluation of

the effects of chemotherapy in patients with advanced
carcinoma of the prostate.
J Urol

1976; 116:211
-
213.


Gibbons RP, Scott WW, Johnson DE, Prout GR, Schmidt JD,
Murphy GP
. Prostatic
carcinoma: Relationship between primary tumor, histologic grade and
response to
chemotherapy.
Urology

1976; 8(3):222
-
226.


Johnson DE, Scott WW, Gibbons RP, Rout GR, Schmidt JD, Chu TM, Gaeta J, Saroff J,
Murphy GP
. National randomized study of chemotherapeutic agents in advanced
prostatic carcinoma: a progress report.
Cancer Treatment Reports

1977; 61(2):317
-
323.


Catane R, Kaufman J, Mittelman A,
Murphy GP
. Disappearance of osteoblastic
metastases in prostatic carcinoma following Estracyt therapy.
J Am Med Assoc

1977;
237(23):2471.


Beckly S, Wajsman Z, Maeso E, Pont
es JE,
Murphy GP
. Estramustine phosphate with
multiple cytotoxic agents in the treatment of advanced prostatic cancer.
Urology

1981;
18(6):592
-
595.


Soloway MS, Beckly S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JR,
Gibbons RP, Loening SA, McKi
el CF, McLeod DG, JM, Pontes JE, Prout GR, Scardino
PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH,
Murphy GP
. A comparison of
estramustine phosphate versus cis
-
platinum alone versus estramustine phosphate plus cis
-
platinum in patients with advanced horm
one refractory prostate cancer who had extensive
irradiation to the pelvis or lumbosacral area.
J Urol

1983; 129(1):56
-
61.


Murphy GP
, Beckly S, Brady MF, Chu TM, deKernion JB, McKiel CF, McLeod DG,
Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt J
D, Scott WW, Slack NH,
Soloway MS. Treatment of newly diagnosed metastatic prostate cancer patients with
chemotherapy agents in combination with hormones versus hormones alone.
Cancer

1983; 51(7):1264
-
1272.


Gibbons RP, Beckly S, Brady MF, Chu TM, deKern
ion JB, Dhabuwala C, Gaeta JF,
Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU,
Schmidt JD, Scott WW, Slack HS, Soloway MS,
Murphy GP
. The addition of
chemotherapy to hormonal therapy for treatment of patients with metastat
ic carcinoma of
the prostate.
J Surg Oncol

1983; 23(2):133
-
142.


Schmidt JD, Gibbons RP,
Murphy GP
, Bartolucci A, Investigators of the National
Prostate Cancer Project. Evaluation of adjuvant estramustine phosphate,
cyclophosphamide and observation only
for node
-
positive patients following radical
prostatectomy and definitive irradiation.
Prostate

1996; 28:51
-
57.



Prostate Cancer

Early Detection


Mettlin C, Lee F, Drago J,
Murphy GP
. Findings on the detection of early prostate
cancer in 2425 men.
Canc
er

1991; 67(12):2949
-
2958.


Mettlin C,
Murphy GP
, Lee F, Littrup P, Chesley A, Babaian R, Badalament R, Kane
RA, Mostofi FK, Investigators of the ACS
-
NPCDP. Characteristics of prostate cancers
detected in a multimodality early detection program.
Cancer

1
993; 72(5):1701
-
1708.


Littrup PJ, Kane RA, Mettlin CJ,
Murphy GP
, Lee F, Toi A, Badalament R, Babaian R.
Cost
-
effective prostate cancer detection: reduction of low
-
yield biopsies.
Cancer
1994;
74(12):3146
-
3158.


Denis LJ,
Murphy GP
, Schröder FH. Report

of the consensus workshop on screening
and global strategy for prostate cancer.
Cancer

1995; 75(5):1187
-
1207.


Mettlin C,
Murphy GP
, Babaian RJ, Chesley A, Kane RA, Littrup PJ, Mostofi FK, Ray
PS, Shanberg AM, Toi A. The results of a five year early pro
state cancer detection
intervention. Investigators of the American Cancer Society National Prostate Cancer
Detection Project.
Cancer

1996; 77(1):150
-
159.



von Eschenbach A, Ho R,
Murphy GP
, Cunningham M, Lins N. American Cancer
Society guidelines for t
he early detection of prostate cancer.
Cancer

1997; 80(9):1805
-
1809.



Prostate Cancer

Endocrine Treatment


Murphy GP
, Boctor ZN, Gailani S, Belmusto L. Hypophysectomy for disseminated
prostatic carcinoma.
J Surg Oncol

1969; 1(1):81
-
95.


Murphy GP
, Reyn
oso G, Schoonees R, Gailani S, Bourke R, Kenny GM, Mirand EA,
Schalch DS. Hypophysectomy and adrenalectomy for disseminated prostatic carcinoma.
J Urol

1971; 195:817
-
825.


West CR,
Murphy GP
. Pituitary ablation and disseminated prostatic carcinoma.
J A
m
Med Assoc

1973; 225(3): 253
-
256.


Merrin C,
Murphy GP
, Chu TM, Mittelman A. Carcinoma of the prostate: long
-
term
survival after bilateral adrenalectomy.
Urology
1974; 3(2):223
-
225.


Murphy GP
, Slack NH. The questionable use of hormone therapy in advan
ced
carcinoma of the prostate.
Urologic Clinics N Am

1980; 7(3):631
-
638.


Murphy GP
, Creco JM, Chin JL, Huben RP, Scott M, deHaan HA. Zoladex (ICI 118,
630): clinical trials of a new lutenizing hormone
-
releasing hormone analog in metastatic
prostatic car
cinoma.
Urology

1987; 29(2):185
-
190.


Denis L,
Murphy GP
. Overview of phase III trials on combined androgen treatment in
patients with metastatic prostate cancer.
Cancer

1993; 72(12):3888
-
3895.


Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren R,

Murphy GP
. The
effect of exogenous testosterone replacement on prostate specific antigen and prostate
specific membrane antigen levels in hypogonadal men.
J Surg Oncol

1995; 59:246
-
250.






Prostate Cancer

Imaging


Wynant GE,
Murphy GP
, Horoszewicz, JS
, Neal CE, Collier BD, Mitchell E, Purnell G,
Tyson I, Abdel
-
Nabi H, Winzelberg G. Immunoscintigraphy of prostatic cancer:
preliminary results with
111
In labeled monoclonal antibody 7E11
-
C5.3 (CYT
-
356).
Prostate

1991; 18(3):229
-
241.


Elgamal A
-
A A, Troyc
hak MJ,
Murphy GP
. ProstaScint® scan may enhance
identification of prostate cancer recurrences after prostatectomy, radiation, or hormone
therapy: analysis of 136 scans of 100 patients.
Prostate

1998; 37:261
-
269.


Murphy GP
, Elgamal A.
-
A A, Troychak MJ,
Kenny GM. Follow
-
up ProstaScint


scans verify detection of occult soft tissue recurrence after failure of primary prostate
cancer therapy.
Prostate

2000; 42:315
-
317.



Prostate Cancer

Immunotherapy


Tjoa B, Erickson S, Barren R, Ragde H, Kenny G, Boynton

A,
Murphy GP
.
In vitro

propagated dendritic cells from prostate cancer patients as a component of prostate cancer
immunotherapy.
Prostate

1995; 27(2):63
-
69.


Murphy GP
, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T cell
therapy of pros
tate cancer using autologous dendritic cells pulsed with HLA
-
A0201
-
specific peptides from prostate
-
specific membrane antigen.
Prostate

1996; 29:371
-
380.


Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL,
Murphy GP
. Presentation of
prostate tumor antigens
by dendritic cells stimulates T
-
cell proliferation and cytotoxicity.
Prostate

1996; 28(1):65
-
69.


Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak
MJ, Boynton AL,
Murphy GP
. Follow
-
up evaluation of prostate cancer patients
infused
with autologous dendritic cells pulsed with PSMA peptides.
Prostate

1997; 32(4):272
-
278.


Murphy GP
, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H,
Kenny GM, Barren RJ, Bowes VA, Gregorakis AK, Holmes EH, Boynton A.L.
Comparison
of serum PSMA, PSA levels with results of cytogen
-
356 Prostascint
scanning in prostatic cancer patients.
Prostate

1997; 33(4):281
-
285.


Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb
OE, Ireton RC, Troychak MJ, Salgaller ML, B
oynton AL,
Murphy GP
. Evaluation of
phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.
Prostate

1998; 36(1):39
-
44.



Murphy GP
, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM,
Troychak MJ, Salgaller ML, Boy
nton AL. Phase II prostate cancer vaccine trial: report
of a study involving 37 patients with disease recurrence following primary treatment.
Prostate

1999; 39(1):54
-
59.


Murphy GP
, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM, Jarisch, J. Higher dose
and l
ess frequent dendritic cell infusions with PSMA peptides in hormone refractory
metastatic prostate cancer patients.

Prostate

2000; 43(1):59
-
62.



PSA (Prostate
-
specific Antigen)



Wang MC, Valenzuela LA,
Murphy GP
, Chu TM. Purification of a human prostat
e
specific antigen.
Invest Urol

1979; 17(2):159
-
163.


Kuriyama M, Wang MC, Lee CL, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura
T,
Murphy GP
, Chu TM. Use of human prostate
-
specific antigen in monitoring prostate
cancer.
Cancer Res

1981; 41(10):
3874
-
3876.


Kuriyama M, Wang MC, Lee CL, Killian CS, Papsidero LD, Inaji H, Loor RM, Lin MF,
Nishiura T, Slack NH,
Murphy GP
, Chu TM. Multiple marker evaluation in prostate
cancer using tissue specific antigens.
J Natl Cancer Inst

1982; 68(1):99
-
105.


Po
ntes JE, Chu TM, Slack N, Karr J,
Murphy GP
. Serum prostatic antigen
measurement in localized prostatic cancer: correlation with clinical course.
J Urol

1982;
128(6):1216
-
1218.


Killian CS, Yang N, Kuriyama M, Vargas FP, Emrich LJ, Slack NH, Wang MD,
Pap
sidero LD,
Murphy GP
, Chu TM, and the investigators of the National Prostatic
Cancer Project. Prognostic importance of prostate
-
specific antigen for monitoring
patients with B
2

to D
1

prostate cancer.
Cancer Res

1985; 45:866
-
891


Killian CS, Emrich LJ, Va
rgas FP, Yang N, Wang MC, Priore RL,
Murphy GP
, Chu
TM. Relative reliability of five serially measured markers for prognosis of progression in
prostate cancer.
J Natl Cancer Inst

1986; 76(2):179
-
185.


Babaian RJ, Mettlin C, Kane R,
Murphy GP
, Lee F, Drago

JR, Chesley A, Investigators
of the American Cancer Society National Prostate Cancer Detection Project. The
relationship of prostate
-
specific antigen to digital rectal examination and transrectal
ultrasonography: findings of the American Cancer Society
-
N
ational Prostate Cancer
Detection Project.
Cancer

1992; 69(5):1195
-
1200.


Kane RA, Littrup PJ, Babaian R, Drago JR, Lee F, Chesley A,
Murphy GP
, Mettlin C,
Investigators of the ACS
-
NPCDP. PSA levels in 1,695 men without evidence of prostate
cancer: findi
ngs from the American Cancer Society
-

National Prostate Cancer Detection
Project.
Cancer

1992; 69(5):l201
-
1207.

Hutter R,
Murphy GP
. American Cancer Society workshop on PSA: benefits and
limitations.
Cancer

1993; 71(8):2677
-
2683.


Mettlin C, Littrup PJ,

Kane RA,
Murphy GP
, Lee F, Chesley A, Badalament R, Mostofi
FK. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level
compared with age
-
referenced PSA, PSA density and PSA change: data from the
American Cancer Society Nation
al Prostate Cancer Detection Project.
Cancer

1994;
74(5):1615
-
1620.


Murphy GP
. The Second Stanford Conference on International Standardization of
Prostate Specific Antigen Assays.
Cancer

1995; 75(1):122
-
128.


Morgan TO, McLeod DG, Leifer ES,
Murphy GP
,

Moul JW. Prospective use of free
prostate
-
specific antigen to avoid repeat prostate biopsies in men with elevated total
prostate
-
specific antigen.
Urology

1996; 48(6A):76
-
80.


Mettlin CJ, Chesley AE,
Murphy GP
, Bartsch G, Toi A, Bahnson R, Church P. Th
e
association of free PSA percent, total PSA, age, and gland volume in the detection of
prostate cancer.
Prostate

1999; 39:153
-
158.


Preston DM, Levin LI, Jacobson DJ, Jacobsen SJ, Rubertone M, Holmes E,
Murphy GP
,
Moul JW. Prostate
-
specific antigen leve
ls in young white and black men age 20 to 45
years old.
Urology

2000; 56(5):812
-
816.



PSMA (Prostate
-
specific Membrane Antigen)


Rochon YP, Horoszewicz JS, Boynton AL, Holmes EH, Barren RJ, Erickson SJ, Kenny
GM,
Murphy GP
. Western blot assay for prosta
te specific membrane antigen in serum
of prostate cancer patients.
Prostate

1994; 25:219
-
223.


Murphy GP
, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, Barren
RJ. A comparison of prostate specific antigen, prostate specific membrane antigen,

and
LNCaP based elisa assays in prostatic cancer patients and patients with benign prostatic
enlargement.
Prostate

1995; 26(4):164
-
168.


Murphy GP
, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H,
Pointner J, Reissigl A, McLeod DG, Dou
glas T, Morgan T, Kenny GM, Ragde H,
Boynton AL, Holmes EH. Evaluation and comparison of two new prostatic cancer
markers: free PSA (f
-
PSA) and prostate specific membrane antigen (PSMA).
Cancer

1996; 78(4):809
-
818.


Bostwick DG, Pacelli A, Blute M, Roche

P,
Murphy GP
. Prostate specific membrane
antigen (PSMA) expression in prostatic intraepithelial neoplasia and adenocarcinoma:
study of 184 cases.
Cancer

1998; 82(11):2256
-
2261.


Prostate Cancer

Other Markers


Murphy GP
, Reynoso G, Kenny GM, Gaeta JF.
Comparison of total and prostatic
fraction serum acid phosphate levels in patients with differentiated and undifferentiated
prostatic carcinoma.
Cancer

1969; 23(6):1309
-
1314.


El
-
Shirbiny A, Bhargava A, Beckly S, Fitzpatrick J,
Murphy GP
. Comparison of
i
mmunologic and enzymatic assay of prostatic acid phosphatase for follow
-
up and
assessment of clinical status of Stage D prostate cancer.
J Surg Oncol

1984; 26(4):256
-
259.


Barren RJ, Holmes EH, Boynton AL, Grigorakis A, Cobb OE, Wilson CL, Ragde H,
Murphy

GP
. A method for identifying prostate cells in semen using flow cytometry.
Prostate

1998; 36(3):181
-
188.


Kim J, Palmer JL, Finn L, Hodges S, Bowes V, Deftos L,
Murphy GP
, Logothetis C.
The pattern of serum markers in select patients with androgen
-
inde
pendent
adenocarcinoma of the prostate.
Urologic Oncology

2000; 5:97
-
103.



Prostate

Non
-
Cancerous Diseases


Karr JP, Kim U, Resko JA, Schneider S, Chai LS,
Murphy GP
, Sandberg AA.
Introduction of benign prostatic hypertrophy in baboons.
Urology

1984; 2
3(3):276
-
289.


Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT
Murphy GP
. The
association of benign prostatic hyperplasia and cancer of the prostate.
Cancer

1992;
70(1):291
-
301.





” is used to designate those articles which are displayed in The
Gallery located in the
Foundation headquarters.


Use Top Navigation tabs to return to the Web Site